CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access ...
ImmunityBio Inc. IBRX on Monday said it entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results